DaVita HealthCare Partners Inc (DVA) Fair Value & Analysis
Healthcare · US · Market cap $14.9B · ISIN US23918K1088
What is DaVita HealthCare Partners Inc really worth?
DaVita HealthCare Partners Inc
DVA · US
A solid business, currently priced close to our fair value of $186.49.
Strengths
Risks
Fair value as of: Sep 1, 2026
From 26 valuation models · updated 3 days ago
Share price −20.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The model range is unusually wide ($73.35 to $233.11). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 1, 2026.
How to read this chart
60‑month range $65.42 – $240.96 · fair‑value band $73.35 – $233.11 · the $181.66 price screens below the $186.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 1, 2026.
Analysis
DaVita HealthCare Partners Inc (DVA) currently trades at $181.66, while our model-based Fair Value estimate is $186.49, implying the stock looks roughly 2.6% fairly valued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of $186.49 per share, and 10 of the 26 models we run sit above the $181.66 price. Bear case: the Dividend Discount group reads lowest at $48.96, and 16 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, DaVita HealthCare Partners Inc generated revenue of $13.8B at a net margin of 5.7%. Revenue grew 6.0% year over year. It earns a return on equity of 81.0%. Net debt stands at $14.3B. Fundamentals as of Sep 1, 2026
Our scenario range runs from $73.35 (bear case) to $233.11 (bull case); at $181.66, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 10% below its 52-week high and 80% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 3%, DVA screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $6.96 per share, which is 3.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Multiples ($186.49) versus Asset-Based ($8.81). Highest evidence: FCF DCF (74).
Notify me when DVA reaches fair value
Put DVA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 1, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 59
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
Full company description
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DaVita HealthCare Partners Inc reported revenue of $13.6B in FY2025 versus $11.6B in FY2021, a compound +4.1%/yr. Reported net income was $747M in FY2025, compounding −6.5%/yr from FY2021.
of which total revenue −0.8 % · buybacks/dilution +10.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch DVA: get an alert when its fair value changes →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- DaVita (DVA) Has Investors Asking A Fresh Question
- Why Is DaVita HealthCare (DVA) Down 4.9% Since Last Earnings Report?
- Do Options Traders Know Something About DaVita Stock We Don't?
Peer Group
Medical Care Facilities · 256 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Sep 1, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $417.82 | $547.67 | +31% |
| Fresenius SE FRE | €45.25 | €32.15 | −29% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 241.00 SAR | 112.37 SAR | −53% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | −46% |
| Tenet Healthcare Corporation THC | $266.80 | $330.25 | +24% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | −66% |
| Fresenius Medical Care AG FME | €39.92 | €71.28 | +79% |
| Aier Eye Hospital Group 300015 | ¥8.25 | ¥7.67 | −7% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,005 | ₹284.87 | −72% |
| Encompass Health Corporation EHC | $120.31 | $109.77 | −9% |
Compare DaVita HealthCare Partners Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is DaVita HealthCare Partners Inc (DVA) overvalued or undervalued?
What is the fair value of DVA?
What is the quality score of DVA?
What is the revenue of DaVita HealthCare Partners Inc (DVA)?
What is the net profit margin of DVA?
Does DaVita HealthCare Partners Inc pay a dividend?
Watch DaVita HealthCare Partners Inc in the live analysis
One click puts DaVita HealthCare Partners Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.